NASDAQ:APM - Nasdaq - KYG6096M1226 - Common Stock - Currency: USD
1.0951
-0.01 (-1.34%)
The current stock price of APM is 1.0951 USD. In the past month the price decreased by -11.33%. In the past year, price decreased by -34.82%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The firm's pipeline is also enriched through the co-development of PathsDx Test, a novel molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore's Agency for Science, Technology and Research.
APTORUM GROUP LTD-CLASS A
17 Hanover Square
London W1S 1BN GB
CEO: Ian Huen
Employees: 3
Company Website: http://www.aptorumgroup.com/
Investor Relations: http://ir.aptorumgroup.com
Phone: 442080929299
The current stock price of APM is 1.0951 USD. The price decreased by -1.34% in the last trading session.
The exchange symbol of APTORUM GROUP LTD-CLASS A is APM and it is listed on the Nasdaq exchange.
APM stock is listed on the Nasdaq exchange.
APTORUM GROUP LTD-CLASS A (APM) has a market capitalization of 7.82M USD. This makes APM a Nano Cap stock.
APTORUM GROUP LTD-CLASS A (APM) currently has 3 employees.
APTORUM GROUP LTD-CLASS A (APM) has a support level at 1.09 and a resistance level at 1.43. Check the full technical report for a detailed analysis of APM support and resistance levels.
The Revenue of APTORUM GROUP LTD-CLASS A (APM) is expected to grow by 9197.28% in the next year. Check the estimates tab for more information on the APM EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
APM does not pay a dividend.
APTORUM GROUP LTD-CLASS A (APM) will report earnings on 2025-04-28, after the market close.
The PE ratio for APTORUM GROUP LTD-CLASS A (APM) is 54.76. This is based on the reported non-GAAP earnings per share of 0.02 and the current share price of 1.0951 USD. Check the full fundamental report for a full analysis of the valuation metrics for APM.
The outstanding short interest for APTORUM GROUP LTD-CLASS A (APM) is 2% of its float. Check the ownership tab for more information on the APM short interest.
ChartMill assigns a technical rating of 3 / 10 to APM. When comparing the yearly performance of all stocks, APM turns out to be only a medium performer in the overall market: it outperformed 68.14% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to APM. APM has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months APM reported a non-GAAP Earnings per Share(EPS) of 0.02. The EPS increased by 100.48% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | 0.11% | ||
ROE | 0.08% | ||
Debt/Equity | 0.14 |
ChartMill assigns a Buy % Consensus number of 80% to APM. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 86.79% and a revenue growth 9197.28% for APM